Jonathan Cohen, Director of Clinical Research at Sharett Institute of Oncology of Hadassah Medical Center, shared on LinkedIn:
“I had the opportunity to discuss various topics in hepatocellular carcinoma at the annual meeting of the Israeli Oncology Society (ISCORT).
Some points of discussion:
- Should all HCC patients undergo biopsies?
– This will probably become SOC soon with ADC’s and other biomarker-driven therapies; but not yet. - When should systemic therapies be introduced?
– Adjuvant data is not ripe, but I would strongly consider when loco-regional disease recurs. Survival data will be crucial.
– Neoadjuvant treatment makes sense. Awaiting data.
– Downstaging with ICI before liver transplant – some ongoing single institution studies. Risk of rejection? Loss of systemic protection due to immune-suppression? vs. potential for cure? - How should increased LFT’s be handled in HCC patients receiving ICI?
– Don’t rush to label as irAE. - What’s going on in the clinical research arena for HCC?
– ADC’s
– Immune-cell engagers
– Novel combinations
– Personalized neoantigen vaccine.”
View additional information.
Source: Jonathan Cohen/LinkedIn